These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10188787)

  • 1. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies.
    Flynn DD; Ferrari-DiLeo G; Levey AI; Mash DC
    Life Sci; 1995; 56(11-12):869-76. PubMed ID: 10188787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease.
    Flynn DD; Ferrari-DiLeo G; Mash DC; Levey AI
    J Neurochem; 1995 Apr; 64(4):1888-91. PubMed ID: 7891119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies.
    Flynn DD; Weinstein DA; Mash DC
    Ann Neurol; 1991 Mar; 29(3):256-62. PubMed ID: 2042942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease.
    Ladner CJ; Celesia GG; Magnuson DJ; Lee JM
    J Neuropathol Exp Neurol; 1995 Nov; 54(6):783-9. PubMed ID: 7595651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters.
    Muma NA; Mariyappa R; Williams K; Lee JM
    Synapse; 2003 Jan; 47(1):58-65. PubMed ID: 12422374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease.
    Ferrari-DiLeo G; Mash DC; Flynn DD
    Mol Chem Neuropathol; 1995 Jan; 24(1):69-91. PubMed ID: 7755848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia.
    Vanderheyden P; Ebinger G; Dierckx R; Vauquelin G
    J Neurol Sci; 1987 Dec; 82(1-3):257-69. PubMed ID: 3440867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex.
    Lai MK; Lai OF; Keene J; Esiri MM; Francis PT; Hope T; Chen CP
    Neurology; 2001 Sep; 57(5):805-11. PubMed ID: 11552008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.
    Araujo DM; Lapchak PA; Robitaille Y; Gauthier S; Quirion R
    J Neurochem; 1988 Jun; 50(6):1914-23. PubMed ID: 3373218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
    Vamvakidès A
    Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.
    Scarr E; McLean C; Dean B
    J Neural Transm (Vienna); 2017 Mar; 124(3):273-284. PubMed ID: 27688247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease.
    Shiozaki K; Iseki E; Uchiyama H; Watanabe Y; Haga T; Kameyama K; Ikeda T; Yamamoto T; Kosaka K
    J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):209-13. PubMed ID: 10406992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: contrast with other dementias.
    Warren NM; Piggott MA; Lees AJ; Perry EK; Burn DJ
    J Chem Neuroanat; 2008 May; 35(3):268-74. PubMed ID: 18282687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M1 muscarinic receptor signaling in mouse hippocampus and cortex.
    Porter AC; Bymaster FP; DeLapp NW; Yamada M; Wess J; Hamilton SE; Nathanson NM; Felder CC
    Brain Res; 2002 Jul; 944(1-2):82-9. PubMed ID: 12106668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
    Burke RE
    Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
    Ladner CJ; Lee JM
    Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction?
    Tayebati SK; Amenta F; Amici S; El-Assouad D; Gallai V; Ricci A; Parnetti L
    J Neuroimmunol; 2001 Dec; 121(1-2):126-31. PubMed ID: 11730949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.